Health Care/Hospital
GenScript Receives Best Cell & Gene Therapy Supplier Award: Gene Editing and GenScript ProBio Receives Best Biologics CMO Awards: Upstream Processing & Analytical Services
SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) and GenScriptProBio (a global one-stop CDMO from GenScript Group) receive 3 awards: Best Cell & Gene Therapy Supplier Award – Gene Editing on the Asia-Pacific Cell & Gene Therapy Excellence ...
2022-09-15 12:34
7281
GILEAD SCIENCES CELEBRATES TOP RANKING BY HEPATITIS & ASIAN PATIENT GROUPS
-- In the recently published PatientView report, Gilead is ranked number one in all corporate reputation indicators by hepatitis patient groups globally -- -- Gilead also ranks first among peers in Asia by patient groups in this region -- HONG KONG, Sept. 15, 2022 /PRNewswire/ -- Gilead Sciences...
2022-09-15 10:00
1846
ClavystBio launches to translate life sciences breakthroughs into health impact
* ClavystBio will invest and work with partners to accelerate life sciences commercialisation inSingapore through three pillars: collaborate, venture and build. * ClavystBio has committed US$220 million to date in investments to launch global life sciences companies fromSingapore. SINGAPORE, ...
2022-09-15 10:00
4243
Juniper Biologics Establishes Global Headquarters in Singapore
Juniper Biologics' investment will support the growth and innovation of Singapore's pharmaceutical sector SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its ...
2022-09-15 09:53
1697
Grand Richmond Hotel Achieves GHA's WellHotel® Accreditation for Medical Travel & Well-being
PALM BEACH GARDENS, Fla., Sept. 14, 2022 /PRNewswire/ -- Grand Richmond Hotel, one ofBangkok's premier hotels was awarded WellHotel® Accreditation for Medical Travel and Well-being byGlobal Healthcare Accreditation (GHA). Setting the standard for luxury events and business and leisure stays, th...
2022-09-14 21:29
1905
HAVAS HEALTH & YOU APPOINTS LAURA MIZRAHI CHIEF CREATIVE OFFICER OF FLAGSHIP AGENCY H4B CHELSEA
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- As modern health brands evolve to meet the need for increasingly integrated experiences between health companies, providers, and patients, Havas Health & You today announced that it has appointed innovative creative leaderLaura Mizrahi as Chief Creative Of...
2022-09-14 21:00
1335
Fosun: Foreign Media Reports about "Regulatory Authorities Asking Banks to Examine their Exposure to Fosun" are Completely False
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false. It is understood that Fosun h...
2022-09-14 17:03
2499
Introducing Crown Aesthetics' International Educational Program for SkinPen® Precision Customers
Crown Aesthetics Elevates its Commitment to Customer Education and Training DALLAS, Sept. 14, 2022 /PRNewswire/ -- Crown Aesthetics ("Crown"), a division of Crown Laboratories, Inc., announced today that its directUnited Kingdom and Ireland ("UKI") team will now offer all UK & Ireland SkinPen Pre...
2022-09-14 14:30
1209
Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, Sept. 14, 2022 /PRNewswire/ --Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST003, its fir...
2022-09-14 14:18
2120
Nippon Express Obtains GDP Certification of Compliance with WHO Standards at East Japan Pharmaceutical Center
- Dedicated Pharmaceutical Logistics Facility Offers Storage and Transport in Two Temperature Ranges - TOKYO, Sept. 14, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereafter "Nippon Express"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired Good Distribution Practice (GDP) cert...
2022-09-14 14:00
1707
Fosun: Foreign Media Reports about "Regulatory Authorities Asking Banks to Examine their Exposure to Fosun" are Completely False
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false. It is understood that Fosun h...
2022-09-14 12:11
2572
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
* 64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 month s,among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS wa...
2022-09-14 09:11
1720
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022
* 2-year survival data of this study were presented: KN046 combined with platinum doublet chemotherapy showed promising efficacy and well tolerated safety as first-line（1L）treatment for advanced NSCLC patients * In 87 efficacy evaluable patients, confirmed ORR was 46%. * Median OS in non-squ...
2022-09-14 09:04
1712
Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)
* As of January 30, 2022,31 patients with HER2-positive unresectable locally advanced or metastatic GC/GEJ, with no prior systemic treatment, were enrolled. 27 patients were evaluable for efficacy. The ORR was 77.8% and DCR was 92.6%. * The phase III pivotal study is planned to confirm the eff...
2022-09-14 09:01
1745
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence
SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help An...
2022-09-14 08:30
3270
FWD announces update to bond consent solicitation and publication of half year results
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- FWD Limited and FWD Group Limited – consolidated subsidiaries of FWD Group Holdings Limited ("FWD Group" or "the Company") – announced updates and additional information, including FWD Group's results for the six months ended30 June 2022, as part of annou...
2022-09-14 08:28
2405
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future LAUSANNE, Switzerland, Sept. 14, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investm...
2022-09-14 00:48
1414
TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism
BIRMINGHAM, England, Sept. 13, 2022 /PRNewswire/ -- Concept Medical
2022-09-13 22:15
1744
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announ...
2022-09-13 22:00
1840
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today ann...
2022-09-13 20:38
1550
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5482
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4443
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4034
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3294
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3039